These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Use of site-directed mutagenesis to elucidate the active site of neutral endopeptidase 24.11 (enkephalinase). Hersh LB NIDA Res Monogr; 1991; 111():188-201. PubMed ID: 1775181 [No Abstract] [Full Text] [Related]
5. Evidence by site-directed mutagenesis that arginine 203 of thermolysin and arginine 717 of neprilysin (neutral endopeptidase) play equivalent critical roles in substrate hydrolysis and inhibitor binding. Marie-Claire C; Ruffet E; Antonczak S; Beaumont A; O'Donohue M; Roques BP; Fournié-Zaluski MC Biochemistry; 1997 Nov; 36(45):13938-45. PubMed ID: 9374873 [TBL] [Abstract][Full Text] [Related]
6. Identification of two arginine residues involved in the binding of substrate to neutral endopeptidase 24-11. Le Moual H; Beaumont A; Roques BP; Crine P; Boileau G Matrix Suppl; 1992; 1():99. PubMed ID: 1480105 [No Abstract] [Full Text] [Related]
7. Neutral endopeptidase expression in mesangial cells. Ebihara F; Di Marco GS; Juliano MA; Casarini DE J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):228-33. PubMed ID: 14689370 [TBL] [Abstract][Full Text] [Related]
8. The ultimate tryptophan residue of neprilysin 2 is not involved in protein maturation and enzymatic activity. Voisin S; Ouimet T Biochem Biophys Res Commun; 2005 Sep; 335(2):356-60. PubMed ID: 16081046 [TBL] [Abstract][Full Text] [Related]
9. A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis. Raguin O; Fournié-Zaluski MC; Romieu A; Pèlegrin A; Chatelet F; Pélaprat D; Barbet J; Roques BP; Gruaz-Guyon A Angew Chem Int Ed Engl; 2005 Jun; 44(26):4058-61. PubMed ID: 15926197 [No Abstract] [Full Text] [Related]
10. Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP; Noble F NIDA Res Monogr; 1995; 147():104-45. PubMed ID: 8742783 [No Abstract] [Full Text] [Related]
11. Neutral endopeptidase inhibitors and endothelin antagonists: why did the clinical trials not demonstrate beneficial effects? Iyengar S; Abraham WT Heart Fail Clin; 2005 Apr; 1(1):95-102. PubMed ID: 17386837 [No Abstract] [Full Text] [Related]
12. Neutral endopeptidase (EC 3.4.24.11): constructed molecular forms show new angles of an old enzyme. Howell S; Boileau G; Crine P Biochem Cell Biol; 1994; 72(3-4):67-9. PubMed ID: 7818851 [No Abstract] [Full Text] [Related]
13. Interaction of mammalian neprilysin with binding protein and calnexin in Schizosaccharomyces pombe. Beaulieu H; Elagöz A; Crine P; Rokeach LA Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):813-9. PubMed ID: 10359668 [TBL] [Abstract][Full Text] [Related]
14. Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV. Oefner C; Pierau S; Schulz H; Dale GE Acta Crystallogr D Biol Crystallogr; 2007 Sep; 63(Pt 9):975-81. PubMed ID: 17704566 [TBL] [Abstract][Full Text] [Related]
15. [Neprilysin--structure of the gene and protein product and the localization of expression]. Kubiak-Wlekły A; Niemir ZI Pol Merkur Lekarski; 2009 Jul; 27(157):48-50. PubMed ID: 19650430 [TBL] [Abstract][Full Text] [Related]
16. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors. Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427 [TBL] [Abstract][Full Text] [Related]
17. Degradation of bradykinin in human urine by carboxypeptidase Y-like exopeptidase and neutral endopeptidase and their inhibition by ebelactone B and phosphoramidon. Saito M; Majima M; Katori M; Sanjou Y; Suyama I; Shiokawa H; Koshiba K; Aoyagi T Int J Tissue React; 1995; 17(5-6):181-90. PubMed ID: 8835628 [TBL] [Abstract][Full Text] [Related]
18. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. Robl JA; Cimarusti MP; Simpkins LM; Brown B; Ryono DE; Bird JE; Asaad MM; Schaeffer TR; Trippodo NC J Med Chem; 1996 Jan; 39(2):494-502. PubMed ID: 8558518 [TBL] [Abstract][Full Text] [Related]
19. M13 endopeptidases: New conserved motifs correlated with structure, and simultaneous phylogenetic occurrence of PHEX and the bony fish. Bianchetti L; Oudet C; Poch O Proteins; 2002 Jun; 47(4):481-8. PubMed ID: 12001226 [TBL] [Abstract][Full Text] [Related]
20. A highly selective assay for neutral endopeptidase based on the cleavage of a fluorogenic substrate related to Leu-enkephalin. Carvalho KM; Boileau G; Camargo AC; Juliano L Anal Biochem; 1996 Jun; 237(2):167-73. PubMed ID: 8660561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]